Expression of selected genes involved with endothelial cell adhesion molecules, tight junction and adherence junction.

Results are shown as fold change of ABC treatment versus other treatment groups. Minus sign denotes down regulation of ABC compared to comparison treatment. P = adjusted significance; ICAM = intracellular adhesion molecule; SELPLG = selectin P ligand; CD40 = TNF receptor superfamily member 5 (CD40); transcript variant 1; JAM = junction adhesion molecule; ITGB1 = integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12);VAPA = Homo sapiens VAMP (vesicle-associated membrane protein)-associated protein A. PPP2R4 = Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit 4; CLDN = claudin mRNA; CTNNA1and B1 Catenin (cadherin-associated protein) alpha1and beta 1; ERBB2 = erythrobalstic leukaemia viral oncogene homolog2, neuro/glioblastoma derived oncogene homolog (avian), transcript variant 2, mRNA; MLLT4 = myeloid leukemia/lymphoid or mixed linage leukaemia; translocated to, 4, transcript variant 3, mRNA
* 14 other variants of PPP2A were also significantly upregulated with ABC 6 months compared to the combined AZT and TDF group (p = 0.009–6.8E–10)
** 4 other variants of PPP2A were upregulated (p = 7.0E–10 to p = 0.003) and 6 variants down regulated (p = 0.0001–0.003)
Pathways: AJ = adherence junction; CAM = cell adhesion molecule; CCR = cytokine-cytokine receptor interaction; NFkB = NF kappa B; LTM = leukocyte transendothelial migration; TJ = tight junction; TLR = toll-like receptors
Expression of selected genes involved with endothelial cell adhesion molecules, tight junction and adherence junction.